USA Financial Formulas Makes New Investment in Insulet Co. (NASDAQ:PODD)

USA Financial Formulas bought a new position in Insulet Co. (NASDAQ:PODD - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 4,725 shares of the medical instruments supplier's stock, valued at approximately $1,234,000.

Other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. raised its holdings in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 58 shares in the last quarter. Venturi Wealth Management LLC boosted its holdings in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after buying an additional 133 shares in the last quarter. TD Private Client Wealth LLC grew its position in shares of Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after buying an additional 56 shares during the period. Friedenthal Financial bought a new position in shares of Insulet in the 4th quarter worth about $57,000. Finally, Versant Capital Management Inc lifted its position in Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier's stock valued at $80,000 after acquiring an additional 157 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on PODD shares. Canaccord Genuity Group upped their price objective on shares of Insulet from $269.00 to $304.00 and gave the stock a "buy" rating in a report on Monday, December 9th. TD Cowen upped their price target on Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, January 3rd. Wells Fargo & Company lifted their price objective on Insulet from $290.00 to $305.00 and gave the company an "overweight" rating in a research note on Wednesday, December 11th. Sanford C. Bernstein initiated coverage on Insulet in a research note on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 target price on the stock. Finally, Citigroup lifted their price target on Insulet from $283.00 to $310.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $272.81.

Insider Transactions at Insulet

In related news, CAO Lauren Budden sold 915 shares of the business's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.47% of the company's stock.

Insulet Stock Performance

Insulet stock traded up $8.27 during midday trading on Thursday, reaching $272.65. 460,139 shares of the company traded hands, compared to its average volume of 496,765. The firm has a market capitalization of $19.12 billion, a price-to-earnings ratio of 46.69, a price-to-earnings-growth ratio of 3.41 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The business has a 50 day moving average of $265.59 and a two-hundred day moving average of $231.62. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.77.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.